| SIRT3 is a mitochondria-localized tumor suppressor required for maintenance of mitochondrial integrity and metabolism during stress HS Kim, K Patel, K Muldoon-Jacobs, KS Bisht, N Aykin-Burns, ... Cancer cell 17 (1), 41-52, 2010 | 899 | 2010 |
| Outcomes of COVID-19 in patients with CLL: a multicenter international experience AR Mato, LE Roeker, N Lamanna, JN Allan, L Leslie, JM Pagel, K Patel, ... Blood, The Journal of the American Society of Hematology 136 (10), 1134-1143, 2020 | 294 | 2020 |
| Use of convalescent plasma in hospitalized patients with COVID-19: case series L Hegerova, TA Gooley, KA Sweerus, C Maree, N Bailey, M Bailey, ... Blood, The Journal of the American Society of Hematology 136 (6), 759-762, 2020 | 133 | 2020 |
| CTCFL/BORIS is a methylation-independent DNA-binding protein that preferentially binds to the paternal H19 differentially methylated region P Nguyen, H Cui, KS Bisht, L Sun, K Patel, RS Lee, H Kugoh, M Oshimura, ... Cancer research 68 (14), 5546-5551, 2008 | 64 | 2008 |
| Protein kinase C isoforms in multidrug resistant P388/ADR cells: a possible role in daunorubicin transport S Gollapudi, K Patel, V Jain, S Gupta Cancer letters 62 (1), 69-75, 1992 | 59 | 1992 |
| Current and future treatment strategies in chronic lymphocytic leukemia K Patel, JM Pagel Journal of hematology & oncology 14 (1), 69, 2021 | 56 | 2021 |
| Pirtobrutinib after a covalent BTK inhibitor in chronic lymphocytic leukemia AR Mato, JA Woyach, JR Brown, P Ghia, K Patel, TA Eyre, T Munir, ... New England Journal of Medicine 389 (1), 33-44, 2023 | 50 | 2023 |
| COVID-19 respiratory failure: targeting inflammation on VV-ECMO support ME Hartman, RA Hernandez, K Patel, TE Wagner, T Trinh, AB Lipke, ... Asaio Journal 66 (6), 603-606, 2020 | 48 | 2020 |
| Febrile neutropenia K Patel, HJ West JAMA oncology 3 (12), 1751-1751, 2017 | 48 | 2017 |
| Zilovertamab vedotin targeting of ROR1 as therapy for lymphoid cancers ML Wang, JC Barrientos, RR Furman, M Mei, PM Barr, MY Choi, S de Vos, ... NEJM evidence 1 (1), EVIDoa2100001, 2022 | 44 | 2022 |
| Safety and efficacy of FT596, a first-in-class, multi-antigen targeted, off-the-shelf, iPSC-derived CD19 CAR NK cell therapy in relapsed/refractory B-cell lymphoma V Bachanova, A Ghobadi, K Patel, JH Park, IW Flinn, P Shah, C Wong, ... Blood 138, 823, 2021 | 42 | 2021 |
| NX-2127-001, a first-in-human trial of NX-2127, a Bruton's tyrosine kinase-targeted protein degrader, in patients with relapsed or refractory chronic lymphocytic leukemia and B … AR Mato, WG Wierda, WZ Ai, IW Flinn, M Tees, MR Patel, K Patel, ... Blood 140 (Supplement 1), 2329-2332, 2022 | 36 | 2022 |
| Mycosis fungoides: developments in incidence, treatment and survival AE Kaufman, K Patel, K Goyal, D O'Leary, N Rubin, D Pearson, ... Journal of the European Academy of Dermatology and Venereology 34 (10), 2288 …, 2020 | 36 | 2020 |
| Duvelisib for CLL/SLL and follicular non-Hodgkin lymphoma K Patel, AV Danilov, JM Pagel Blood, The Journal of the American Society of Hematology 134 (19), 1573-1577, 2019 | 35 | 2019 |
| Use of the IL‐6R antagonist tocilizumab in hospitalized COVID‐19 patients K Patel, TA Gooley, N Bailey, M Bailey, L Hegerova, A Batchelder, ... Journal of internal medicine 289 (3), 430, 2021 | 33 | 2021 |
| Ongoing results of a phase 1B/2 dose-escalation and cohort-expansion study of the selective, noncovalent, reversible Bruton's tyrosine kinase inhibitor, vecabrutinib, in B-cell … JN Allan, K Patel, AR Mato, WG Wierda, JP Ibarz, MY Choi, SM O'Brien, ... Blood 134, 3041, 2019 | 32 | 2019 |
| The enrichment of an alkaliphilic biofilm consortia capable of the anaerobic degradation of isosaccharinic acid from cellulosic materials incubated within an anthropogenic … CJ Charles, SP Rout, EJ Garratt, K Patel, AP Laws, PN Humphreys FEMS microbiology ecology 91 (8), fiv085, 2015 | 32 | 2015 |
| The chronic lymphocytic leukemia comorbidity index (CLL-CI): a three-factor comorbidity model MJ Gordon, A Kaempf, A Sitlinger, G Shouse, M Mei, DM Brander, ... Clinical Cancer Research 27 (17), 4814-4824, 2021 | 30 | 2021 |
| VLS-101, a ROR1-targeting antibody-drug conjugate, demonstrates a predictable safety profile and clinical efficacy in patients with heavily pretreated mantle cell lymphoma and … M Wang, JC Barrientos, RR Furman, M Mei, PM Barr, MY Choi, S de Vos, ... Blood 136, 13-14, 2020 | 28 | 2020 |
| Preliminary safety and anti-tumor activity of XmAb13676, an anti-CD20 x anti-CD3 bispecific antibody, in patients with relapsed/refractory non-Hodgkin's lymphoma and chronic … K Patel, JM Michot, AA Chanan-Khan, GA Salles, G Cartron, F Peyrade, ... Blood 134, 4079, 2019 | 26 | 2019 |
